Biomaterials That Induce Immunogenic Cell Death.
Di LiSiqi LiuYang MaShixian LiuYa-Hui LiuJian-Xun DingPublished in: Small methods (2023)
The immune system takes part in most physiological and pathological processes of the body, including the occurrence and development of cancer. Immunotherapy provides a promising modality for inhibition and even the cure of cancer. During immunotherapy, the immunogenic cell death (ICD) of tumor cells induced by chemotherapy, radiotherapy, phototherapy, bioactive materials, and so forth, triggers a series of cellular responses by causing the release of tumor-associated antigens and damage-associated molecular patterns, which ultimately activate innate and adaptive immune responses. Among them, the ICD-induced biomaterials attract increasing conditions as a benefit of biosafety and multifunctional modifications. This Review summarizes the research progress in biomaterials for inducing ICD via triggering endoplasmic reticulum oxidative stress, mitochondrial dysfunction, and cell membrane rupture and discusses the application prospects of ICD-inducing biomaterials in clinical practice for cancer immunotherapy.
Keyphrases
- cell death
- immune response
- tissue engineering
- oxidative stress
- endoplasmic reticulum
- bone regeneration
- diabetic rats
- clinical practice
- locally advanced
- cell cycle arrest
- radiation therapy
- early stage
- risk assessment
- dendritic cells
- toll like receptor
- cancer therapy
- radiation induced
- squamous cell carcinoma
- papillary thyroid
- squamous cell
- ischemia reperfusion injury
- signaling pathway
- drug induced
- single molecule
- childhood cancer